An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation.
ADP-Ribosylation
/ drug effects
Amino Acid Sequence
Antibodies
/ metabolism
Benzimidazoles
/ pharmacology
Carrier Proteins
/ metabolism
Cell Line, Tumor
Cell Surface Display Techniques
DNA Damage
Glycoside Hydrolases
/ metabolism
Histones
/ metabolism
Humans
Nuclear Proteins
/ metabolism
Phosphates
/ metabolism
Phosphoric Monoester Hydrolases
/ metabolism
Phthalazines
/ pharmacology
Piperazines
/ pharmacology
Poly (ADP-Ribose) Polymerase-1
/ chemistry
Recombinant Proteins
/ metabolism
Serine
/ metabolism
Tyrosine
/ metabolism
ADP-ribosylation
DNA damage
HFP1
MARylation
PARP1
antibodies
chemical biology
histones
mono-ADP-ribosylation
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
12 11 2020
12 11 2020
Historique:
received:
27
04
2020
revised:
27
07
2020
accepted:
22
09
2020
entrez:
13
11
2020
pubmed:
14
11
2020
medline:
20
5
2021
Statut:
ppublish
Résumé
Strategies for installing authentic ADP-ribosylation (ADPr) at desired positions are fundamental for creating the tools needed to explore this elusive post-translational modification (PTM) in essential cellular processes. Here, we describe a phospho-guided chemoenzymatic approach based on the Ser-ADPr writer complex for rapid, scalable preparation of a panel of pure, precisely modified peptides. Integrating this methodology with phage display technology, we have developed site-specific as well as broad-specificity antibodies to mono-ADPr. These recombinant antibodies have been selected and characterized using multiple ADP-ribosylated peptides and tested by immunoblotting and immunofluorescence for their ability to detect physiological ADPr events. Mono-ADPr proteomics and poly-to-mono comparisons at the modification site level have revealed the prevalence of mono-ADPr upon DNA damage and illustrated its dependence on PARG and ARH3. These and future tools created on our versatile chemical biology-recombinant antibody platform have broad potential to elucidate ADPr signaling pathways in health and disease.
Identifiants
pubmed: 33186521
pii: S0092-8674(20)31252-6
doi: 10.1016/j.cell.2020.09.055
pii:
doi:
Substances chimiques
Antibodies
0
Benzimidazoles
0
Carrier Proteins
0
HPF1 protein, human
0
Histones
0
Nuclear Proteins
0
Phosphates
0
Phthalazines
0
Piperazines
0
Recombinant Proteins
0
veliparib
01O4K0631N
Tyrosine
42HK56048U
Serine
452VLY9402
PARP1 protein, human
EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1
EC 2.4.2.30
Phosphoric Monoester Hydrolases
EC 3.1.3.2
Glycoside Hydrolases
EC 3.2.1.-
ADPRS protein, human
EC 3.2.1.143
olaparib
WOH1JD9AR8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1102.e23Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests I.M., J.J.B., and T.C. are inventors on EU patent applications PCT/EP2018/078592 and PCT/EP2019/074885 filled by the Max Planck Society and related to the technology for site-specific generation of Ser-ADP-ribosylated peptides.